Literature DB >> 19775770

HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C.

Stella De Nicola, Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19775770     DOI: 10.1016/j.jhep.2009.08.001

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  9 in total

1.  Natural history of HCV infection.

Authors:  Shiv K Sarin; Manoj Kumar
Journal:  Hepatol Int       Date:  2012-03-09       Impact factor: 6.047

2.  Prediction of Cirrhosis in Patients with Chronic Hepatitis C by Genotype 3.

Authors:  Tarana Gupta; Hari K Aggarwal; Sandeep Goyal; Virendra Singh
Journal:  Euroasian J Hepatogastroenterol       Date:  2020 Jan-Jun

3.  Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

Authors:  Luis Margusino-Framiñán; Purificación Cid-Silva; Sandra Rotea-Salvo; Álvaro Mena-de-Cea; Francisco Suárez-López; Pilar Vázquez-Rodríguez; Manuel Delgado-Blanco; Ana Isabel Sanclaudio-Luhia; Isabel Martín-Herranz; Ángeles Castro-Iglesias
Journal:  Eur J Hosp Pharm       Date:  2020-02-07

4.  Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.

Authors:  Patrizia Carrieri; Fabrice Carrat; Vincent Di Beo; Marc Bourlière; Tangui Barré; Victor De Ledinghen; Georges-Philippe Pageaux; Morgane Bureau; Carole Cagnot; Céline Dorival; Elisabeth Delarocque-Astagneau; Fabienne Marcellin; Stanislas Pol; Hélène Fontaine; Camelia Protopopescu
Journal:  JHEP Rep       Date:  2022-03-30

5.  Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.

Authors:  Masaya Sato; Mayuko Kondo; Ryosuke Tateishi; Naoto Fujiwara; Naoya Kato; Haruhiko Yoshida; Masataka Taguri; Kazuhiko Koike
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

6.  Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.

Authors:  David Wyles; Fred Poordad; Stanley Wang; Laurent Alric; Franco Felizarta; Paul Y Kwo; Benedict Maliakkal; Kosh Agarwal; Tarek Hassanein; Frank Weilert; Samuel S Lee; Jens Kort; Sandra S Lovell; Ran Liu; Chih-Wei Lin; Tami Pilot-Matias; Preethi Krishnan; Federico J Mensa
Journal:  Hepatology       Date:  2018-01-04       Impact factor: 17.425

7.  Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.

Authors:  Steven Flamm; David Mutimer; Armen Asatryan; Stanley Wang; Jürgen Rockstroh; Yves Horsmans; Paul Y Kwo; Ola Weiland; Erica Villa; Jeong Heo; Edward Gane; Stephen D Ryder; Tania M Welzel; Peter J Ruane; Kosh Agarwal; Teresa I Ng; Zhenyi Xue; Sandra S Lovell; Preethi Krishnan; Sarah Kopecky-Bromberg; Roger Trinh; Federico J Mensa; David L Wyles
Journal:  J Viral Hepat       Date:  2018-12-11       Impact factor: 3.728

Review 8.  APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Mamun Al-Mahtab; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-05-26       Impact factor: 6.047

9.  Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar.

Authors:  Lara K Marquez; Antoine Chaillon; Kyi Pyar Soe; Derek C Johnson; Jean-Marc Zosso; Andrea Incerti; Anne Loarec; Aude Nguyen; Josephine G Walker; Nyashadzaishe Mafirakureva; Vincent Lo Re Iii; Adriane Wynn; Craig McIntosh; Susan M Kiene; Stephanie Brodine; Richard S Garfein; Peter Vickerman; Natasha K Martin
Journal:  BMJ Glob Health       Date:  2021-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.